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ABSTRACT
Objective: Olmesartan (OLM) is the latest molecule of registered and marketed in Albania for the treatment of arterial hypertension. This study aims 
to carry out a quality control (QC) test on all the alternatives available in the Albanian market and evaluate if there are any outstanding differences 
terms of quality as it is in terms of price.
Methods: There were carried out various QC pharmacopeias tests on a range of different productions of OLM 20 mg tablets. There have been carried 
out weight variation test, setting the diameter, thickness, friability, hardness, disintegration, and dissolution test. The pharmaceutical equivalents were 
compared to the reference product in terms of similar dissolution factor (f2) of dissolution profiles and the dissolution efficiency. The dissolution test was 
carried out using Varian dissolution apparatus 2 (50 rpm, 37±0.5°C); Varian Prostar high-performance liquid chromatography was used to determine the 
OLM concentration at wavelength 250 nm; Varian hardness VK 200, Guoming BJ-2 disintegration apparatus were used for the respective tests.
Results: The study showed that although there is a consistent difference in market price, their quality is comparable. The dissolution profiles were 
very similar. All formulations met the standards of the United States Pharmacopoeia.
Conclusion: All tablets were within the pharmacopoeia limits. The present study confirmed that the difference in price not always represents a 
difference in terms of quality.
Keywords: Olmesartan medoxomil, Quality control, Pharmacopoeia standards.
INTRODUCTION
According to the data of Global Burden of Disease, arterial hypertension 
(AHT) is the second risk factor for all other kind of diseases in Albania 
for 2010 after the risk factors in connection with diet (Fig. 1) [1,2].
Olmesartan (OLM) is the latest molecule from the group of an 
antagonist of angiotensin inhibitor registered and marketed in 
Albania. It is one of the preferred preparations available for the 
treatment of AHT and part of the national reimbursement list. 
OLM medoxomil is 5-methyl-2-oxo-2H-1,3-dioxol-4-yl) methyl 
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl) 
phenyl] phenyl} methyl)-1H-imidazole-5-carboxylate (Fig. 2). It is a 
potent and selective angiotensin AT1 receptor blocker [3] which has 
been approved for the treatment of hypertension in the US, Japan, 
European countries, and Albania.
The drug contains a medoxomil ester moiety and is cleaved rapidly by 
an endogenous esterase to release the active metabolite OLM.
So, it was decided to carry out a quality control (QC) for different 
products OLM medoxomil sold in the Albanian pharmaceutical market. 
4 generic drugs OLM medoxomil 20 mg were the subject of this study.
METHODS
Four different products OLM medoxomil purchased directly from 
pharmacies in Tirana, Albania (Table 1).
OLM medoxomil as reference standard; analytical balance APX-20 
“Denver instrument; ph meter ultrabasic “Denver instrument”; It was 
conducted a United States Pharmacopoeia (USP) method for dissolution 
test; all chemicals and reagents were high-performance liquid 
chromatography (HPLC) grade, acetonitrile (9.8% pure); potassium 
phosphate monobasic (136.9 g/mol), phosphoric acid concentrated, 
a Varian ProStar HPLC system DAD detector, manual Rheodyne loop 
injection. The separation was performed on an analytical 250 × 4.6 mm 
Eurospher 100−5 C18 (5 μm, particle size) column. The wavelength was 
set at 250 nm. The mobile phase was a mixture of acetonitrile: Phosphate 
buffer (17:33) at pH 3.4 was selected a flow rate of 1.5 mL/min. The 
mobile phase was prepared daily and degassed by ultrasonication for 
5 minutes before use.
The QC tests of tablets consisted of hardness, shape, diameter, 
thickness, disintegration, dissolution, percentage of content of the 
active ingredient.
Weight variation
20 tablets per each production of OLM medoxomil were weighted one 
after the other through an analytical balance, and it was calculated the 
average weight per each product. It was calculated as well the standard 
deviation (SD) [4].
Hardness
The hardness of 10 tablets per each product was measured using 
Varian VK200. Then, it was calculated the mean value and respective 
SD (Table 2) [5].
According to USP, the value of hardness of tablets should vary from 4 
to 10 kgf.
Diameter and thickness
Diameter and thickness of 10 different tablets for each production are 
measured by Caliber WT. It is calculated the mean value of diameter and 
thickness along with the SD [6].
Disintegration
6 tablets of each sample were the subject to a disintegration test using 
Guoming BJ-2 apparatus set at 30 cycles/min, at 37±0.5°C, 1 L of 
distilled water as medium.
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For each of the generics included in the study has been determined the 
mean time of disintegration (Table 2).
The test lasts 30 minutes for each formulation. According to USP, 
“the test is considered passed if all 6 tablets of the first series are 
disintegrated within the time limit. If only one of the tablets does not 
pass the test, it should be repeated with another series of 6 tablets [7].”
The active ingredient content test
The percentage of the content test has been based on the monography 
of OLM medoxomil described in the USP. According to USP, the OLM 
tablets should contain not <90% and not more than 110% OLM 
medoxomil, comparing to the quantity declared in the label. The results 
of this test are included in Table 3.
Calibration curve
The linearity of instrument standard response was determined for each 
compound with different concentration calibration standards ranging 
from 50 µg/ml; 80 µg/ml; 100 µg/ml for OLM. The calibration curve of 
OLM was constructed by plotting analyte peak area ratio as compared 
to the corresponding concentration and fitting these data in regression 
analysis.
Dissolution
Under the described chromatographic conditions, OLM peak was 
well resolved. The final results of the dissolution test on each tablet 
production are listed in Table 4. The Fig. 3 shows the dissolution profiles. 
Dissolution efficiency (DE), the area under a dissolution curve between 
defined time points, and the fit factors (f1 and f2) have been compared for 
the characterization of dissolution profiles. The DE of a pharmaceutical 
form (Khan and Rhodes 1972; Khan 1975) was defined as area under 
the dissolution curve up to a certain time, t, expressed as a percentage 
of the area of the rectangle described by 100% dissolution in the same 
time [8]. DE estimated the release of the active pharmaceutical substance 
into the absorptive medium. The determination has been done for every 
6 vessels, and a mean value was obtained along with a confidence 
interval of 95%. It was used t test for a statistical reason to show any 
possible difference in the %DE 45 minutes of the generics compared to 
the reference III (significance difference *p<0.05).
Calculations in connection with DE [9,10] have been done according to 





























































Rt and Tt were percentages of drug release of the reference product and 
generic product in time t; n was the number of points were the samples 
of both reference and generic were released above 90%.
Table 1: These are doses and prices of subjects of this study
Name Dose (mg) Price (euro)/tab
Generic I 20 0.62
Generic II 20 0.45
Generic III 20 0.17
Generic IV 20 0.15
Fig. 1: The increase of death rate as a consequence of arterial 
hypertension in Albania from 1990 to 2010 [1]
Fig. 2: Structure of olmesartan [3]
Fig. 3: Calibration curve
Table 2: Results of weight variation test, hardness, diameter, thickness, and disintegration time










Generic I 0.219 g (0.82) 11.6±6.4 (5.6) 8.64±0.005 (0.06) 3.74±0.004 (0.12) 15.17±0.4 (2.7)
Generic II 0.222 g (1.24) 8.4±3.7 (4.5) 8.66±0.004 (0.05) 3.86±0.005 (0.14) 15.17±0.14 (2.9)
Generic III 0.213 g (6.7) 10.5±6.7 (9.4) 8.54±0.005 (0.12) 3.62±0.004 (0.12) 15.0±0 (0)
Generic IV 0.216 g (2.09) 10.4±2.1 (2.06) 8.66±0.009 (0.1) 3.62±0.004 (0.12) 15.93±0.17 (1.09)
SD: Standard deviation, RSD: Relative standard deviation
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RESULTS AND DISCUSSION
The main objective of any pharmacopeia is to provide the manufacturers 
of drugs and pharmaceutical dosage forms with a series of QC tests that 
ensures high quality of the final obtained dosage forms. There are in 
the market various productions of the same active ingredient and same 
pharmaceutical form dosage. These productions are considered as 
equivalents, and all of them are part of the reimbursement list. Thus, it is 
very important to see if there is a correlation between price and quality. 
This is what this study do, using the same methods of QC according to 
the same pharmacopoeia (USP), using the same instruments.
Weight variation
The results obtained from this test are listed in Table 2. As it can be 
noticed generic 3 has a relative SD (RSD) by 6.7%, while all other 
generics, from a statistical point of view, have a non-significant 
deviation. All tablets complied with the standards of the USP regarding 
weight variation [10].
Hardness
The results listed in Table 2, show that formulation II hardness value is 
within the range of USP while all 3 others have values upper than 10 kgf. 
Generic I has the highest deviation (RSD 5.6%).
Disintegration
The results of disintegration test are included in Table 2. It can be 
noticed that all productions are disintegrated within 30 minutes, so 
they pass this test.
Percentage of content of the active ingredient
The results of the determination of the content of the active ingredient 
are listed in Table 3. All tablets pass this test because they contain ≥99% 
of the active ingredient showed in the label (Fig. 3).
Generic III has the highest value of the content of the active ingredient 
while all formulations are within the limits of USP for this test. 
Generic III contains 99.9% OLM medoxomil, Generic I 99.5%, Generic II 
99.0%, and Generic IV only 95.5% OLM medoxomil.
Dissolution
The results of the dissolution test on each tablet are listed in Table 4. It 
can be noticed that all tablets dissolved within 30 minutes, on average 
more than 75% of the active ingredient.
From the data in the table, it can be said that at the end of 45 minutes 
all formulations release more than 95% of the active ingredient. 
Comparing these data, Generic III has the best dissolution profile. This 
result is expressed also in the Fig. 4.
Comparison of dissolution profiles
The brand patent is not registered in Albania. So, as long as the 
Generic III has the best dissolution profile, it was decided to compare 
the other 3 productions with it.
As it is shown in Table 5, the t45 minutes values of generics are similar to 
the reference (*p<0.05), confirming a similarity in the dissolution 
process. DE (%DE45 minutes) values of the methods used in this study 
show no significant statistical difference between the reference and 
other generics (*p<0.05). The factors of similarity and difference 
demonstrate similarity since the f1 values are within range 0-15, and 
the f2 values are within 50-100.
The QC test showed that there is no significant difference between 
different generics of OLM medoxomil, marketed in Albania. Even other 
studies show that the QC tests, especially the dissolution test, may serve 
as tools for comparing the generics with a reference or just generics 
between them, through similarity factors and DE. In another step, they 
may serve as a tool for health authorities and specialists during the 
preparation of the drug reimbursement list.
CONCLUSIONS
Taking into account the results of QC tests carried out during this 
study, all different productions of OLM available in the Albanian market 
meet the requirements of USP. The average mass of the 20 tablets was 
within the limits of 85-115% of the average weight and the percentage 
RSD < 10%.
As a conclusion after the hardness test, it can be said that apart 
formulation II, the other formulations were harder by approximately 
1% than the upper limit specified by USP. Regarding the diameter and 
thickness, there were no significant differences.
Comparing the time of disintegration of the tablets of OLM, it can be 
concluded that they are very similar, independently from the difference 
in hardness value.
Regarding the percentage of content of the active ingredient although 
Generic III has a low price 0.17 €/tab it contains 99.9% OLM medoxomil, 
whereas Generic I is the most expensive alternative in the National List 
of Reimbursement, costs 0.62 €/tab (quite 4 times more then Generic I) 
and contains 99.5% OLM medoxomil.
Fig. 4: Dissolution profiles of different olmesartan tablets 20 mg 
Table 3: The content of active ingredient in %





Table 4: Results of dissolution test of different OLM tablets 










Generic I 36.50 77.90 99.70
Generic II 38.40 83.20 99.74
Generic III 40.00 88.80 100.00
Generic IV 33.24 76.30 95.60
OLM: Olmesartan
Table 5: Comparison of dissolution profiles and 









Reference III 100.00 - -
Generic I 99.70 2.58 79.5
Generic II 99.74 6.32 63.1
Generic IV 95.60 10.3 53.3
OLM: Olmesartan
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As a conclusion, it should be said that higher prices not always means 
higher quality. All four formulations are similar in quality, but different 
as far as it concerns the prices.
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